BillionToOne is trading 6.00% up at $120.73 in pre-market on November 5 after third-quarter revenue rose 47% year over year to $123.0 million, above estimates.
- Diluted EPS was $0.32, also ahead of expectations.
- BillionToOne raised its 2026 revenue outlook to $460 million–$470 million from $450 million–$465 million.
- Biotech gained 2.08% in pre-market, providing supportive sector context; available reporting does not independently verify the share move.